secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0000950170-24-121827
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam Pharma Q3 net loss $16.6M; Phase 3 TANDEM topline expected Q4 2024
-------------------------------------------------------------------------------

- Cash $422.7M as of Sep 30, 2024, up from $340.5M at Dec 31, 2023.
- Revenue $29.1M in Q3 2024 from Menarini milestone; net loss $16.6M vs $47.1M in Q3 2023.
- Phase 3 TANDEM topline data now expected in Q4 2024 due to faster enrollment.
- On track for BROADWAY topline data in Q4 2024; BROOKLYN data at AHA Nov 16-18.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000095017024121827/0000950170-24-121827-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000095017024121827/nams-20241106.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-121827

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer